Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 12:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 103 matching trials from the live ClinicalTrials.gov search.
Conditions
Multiple System Atrophy (MSA)
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Autonomic Nervous System Disorders, Pure Autonomic Failure, Shy-Drager Syndrome, Orthostatic Hypotension, Dysautonomic
Interventions
Angiotensin-(1-7), Saline
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Parkinson Disease, Multiple System Atrophy, Progressive Supranuclear Palsy
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Multiple System Atrophy
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years to 80 Years
Enrollment
29 participants
Timeline
2020 – 2024
U.S. locations
1
States / cities
New York, New York
Conditions
Multiple System Atrophy
Interventions
Foralumab Nasal
Drug
Lead sponsor
Tiziana Life Sciences LTD
Industry
Eligibility
30 Years to 85 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Multiple System Atrophy
Interventions
intravenous immunoglobulin (IVIg)
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Worcester, Massachusetts
Active, not recruiting Phase 1 Interventional

GDNF Gene Therapy for Multiple System Atrophy

NCT04680065
Conditions
Multiple System Atrophy
Interventions
AAV2-GDNF gene therapy, Sham (Placebo) Surgery
Biological · Procedure
Lead sponsor
Brain Neurotherapy Bio, Inc.
Industry
Eligibility
35 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
7
States / cities
Irvine, California • Boca Raton, Florida • Boston, Massachusetts + 4 more
Conditions
Multiple System Atrophy
Interventions
ATH434 dose level 1, ATH434 dose level 2, Placebo
Drug
Lead sponsor
Alterity Therapeutics
Industry
Eligibility
30 Years to 75 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
La Jolla, California • Chicago, Illinois • Baltimore, Maryland + 3 more
Conditions
Multiple System Atrophy
Interventions
Verdiperstat, Placebo
Drug
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
29
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 22 more
Conditions
Multiple System Atrophy
Interventions
HB-adMSCs - Hope Biosciences Adipose Derived Mesenchymal Stem Cells
Biological
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
18 Years to 85 Years
U.S. locations
1
States / cities
Sugar Land, Texas
Conditions
Orthostatic Hypotension, Pure Autonomic Failure, Multiple System Atrophy, Autonomic Failure
Interventions
Abdominal compression, Sham abdominal compression, Placebo pill, midodrine
Other · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Multiple System Atrophy (MSA)
Interventions
ONO-2808, Placebo
Drug
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Industry
Eligibility
30 Years to 80 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
30
States / cities
Fountain Valley, California • Los Angeles, California • Palo Alto, California + 23 more
Enrolling by invitation No phase listed Observational

North American Prodromal Synucleinopathy Consortium

NCT03623672
Conditions
REM Sleep Behavior Disorder, Parkinson Disease, Lewy Body Disease, Dementia With Lewy Bodies, Multiple System Atrophy, REM Sleep Parasomnias
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
9
States / cities
Sun City, Arizona • Los Angeles, California • Redwood City, California + 6 more
Terminated Phase 3 Interventional Results available

Study of Rifampicin in Multiple System Atrophy

NCT01287221
Conditions
Multiple System Atrophy
Interventions
Rifampicin, placebo
Drug
Lead sponsor
Phillip Low
Other
Eligibility
30 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
10
States / cities
Los Angeles, California • San Diego, California • Jacksonville, Florida + 7 more
Terminated Early Phase 1 Interventional

Water and Sudafed in Autonomic Failure

NCT02149901
Conditions
Shy-Drager Syndrome, Multiple System Atrophy
Interventions
Pseudoephedrine + 480 ml water, Pseudoephedrine + 50 ml water, Placebo + 480 ml water (optional), Placebo + 50 ml water (optional)
Drug · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Hypertension, Pure Autonomic Failure, Multiple System Atrophy
Interventions
BQ123, Saline
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Multiple System Atrophy
Interventions
ATH434
Drug
Lead sponsor
Alterity Therapeutics
Industry
Eligibility
30 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Completed Not applicable Interventional Results available

Nebivolol in the Supine Hypertension of Autonomic Failure

NCT01044693
Conditions
Hypertension, Pure Autonomic Failure, Multiple System Atrophy
Interventions
Placebo, Nebivolol 5 mg, metoprolol tartrate 50 mg, Sildenafil25 mg
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Multiple System Atrophy
Interventions
Autologous Mesenchymal Stem Cells, Placebo
Biological · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 70 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Neurodegenerative Diseases, sca3, MSA - Multiple System Atrophy, Ataxia, Synucleinopathies
Interventions
18F-PBR06, 18F-PBR06
Drug · Radiation
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Not listed No phase listed Observational Accepts healthy volunteers

Diagnostic and Prognostic Biomarkers in Parkinson Disease

NCT00653783
Conditions
Parkinson Disease, Multiple System Atrophy, Progressive Supranuclear Palsy
Interventions
Not listed
Lead sponsor
The Parkinson Study Group
Network
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Rochester, New York
Conditions
Parkinson's Disease, Multiple System Atrophy, Autonomic Failure
Interventions
13N-Ammonia, 18F-DOPA, 11C-Methylreboxetine (11C-MRB), 18F-Dopamine
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 120 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Parkinson's Disease (PD), Parkinsonism, Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA)
Interventions
Not listed
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
21 Years to 90 Years
Enrollment
290 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2019
U.S. locations
1
States / cities
Hershey, Pennsylvania
Conditions
Hypertension, Pure Autonomic Failure, Multiple System Atrophy, Autonomic Failure
Interventions
Heating pad, Sham control
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee